Jazz Pharmaceuticals (JAZZ) PT Raised to $199 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at Piper Jaffray
February 28, 2018 6:11 AM ESTPiper Jaffray raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $194.00) while maintaining a Overweight rating.
Analyst David Amsellem raises his PT and remains positive noting higher sales estimate, specifically for Vyxeos. The analyst also comments "We think JAZZ... More
Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 6c; Guides FY18 Relatively In-Line
February 27, 2018 4:08 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.95, $0.06 worse than the analyst estimate of $3.01. Revenue for the quarter came in at $436.4 million versus the consensus estimate of $441.31 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2018 EPS of $12.65-$13.25, versus the consensus of $13.07.... More
